You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Dopamine D2 and D3 receptor agonist; Ki values are 5.7 and 3.4 nM respectively.
Sold with the permission of Eli Lilly and Company
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 319.27. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||12.53 mL||62.64 mL||125.29 mL|
|1.25 mM||2.51 mL||12.53 mL||25.06 mL|
|2.5 mM||1.25 mL||6.26 mL||12.53 mL|
|12.5 mM||0.25 mL||1.25 mL||2.51 mL|
References are publications that support the biological activity of the product.
Foreman et al (1989) Preclinical studies on quinelorane, a potent and highly selective D2-DArgic agonist. J.Pharmacol.Exp.Ther. 250 227 PMID: 2526214
Eaton et al (1994) Effects of the selective DArgic D2 agonist quinelorane on the activity of DArgic and noradrenergic neurons projecting to the diencephalon of the rat. J.Pharmacol.Exp.Ther. 268 645 PMID: 7906734
Flietstra and Levant (1998) Comparison of D2 and D3 DA receptor affinity of DArgic compounds in the rat brain. Life Sci. 62 1825 PMID: 9600324
If you know of a relevant reference for Quinelorane hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Quinelorane hydrochloride, Quinelorane hydrochloride supplier, D2, D3, agonists, Dopamine, D2-like, Non-Selective, Receptors, dopaminergic, LY163502, LY, 163502, Non-selective, 1519, Tocris Bioscience
1 Citation for Quinelorane hydrochloride
Citations are publications that use Tocris products. Selected citations for Quinelorane hydrochloride include:
Baca et al (2013) Gene-environment interactions affect long-term depression (LTD) through changes in DA receptor affinity in Snap25 deficient mice. Brain Res 1532 85 PMID: 23939223
Do you know of a great paper that uses Quinelorane hydrochloride from Tocris? Please let us know.
Reviews for Quinelorane hydrochloride
There are currently no reviews for this product. Be the first to review Quinelorane hydrochloride and earn rewards!
Have you used Quinelorane hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.